Table 2.
The most predictive peaks for delta heightSDS 0-2 year identified by regression analysis
| Group | Patients (n=) | Peaks (n=) | R2 | Cross-validated R2 | p-value | Peak m/z value (kDa) |
| GHD | 39 | 7 | 0,73 | 0,61 | 0,032 | 3.160, 3.318, 8.767 (Apo A-II), 9.135, 9.642, 12.872 (TTR), 17.390 (Apo A-II) |
| GHD | 39 | 4 | 0,64 | 0,53 | 0,017 | 4.408 (Apo A-II), 8.696 (Apo A-II), 9.019 (Apo A-II), 17.146 (Apo A-II) |
| ISS | 89 | 8 | 0,47 | 0,35 | 0,015 | 3.160, 4.470, 6.857 (Apo C-I), 8.767 (Apo A-II), 8.875 (Apo A-II), 9.425 (Apo C-III), 12.607 (SAA4), 12.872 (TTR) |
| Total | 128 | 8 | 0,38 | 0,28 | 0,003 | 4.628, 4.470, 4.793, 8.817, 8.875, 9.019, 12.872, 17.146 |
| GHD | 39 | 4 | 0,59 | 0,48 | 0,026 | 4.138, 8.817 (Apo A-II), 9.019 (Apo A-II), 17.262 (Apo A-II) |
| Total | 128 | 8 | 0,35 | 0,24 | 0,003 | 4.138, 8.636 (Apo A-II), 8.875 (Apo A-II), 9.135, 9.425 (Apo C-III), 14.055 (TTR), 28.090 (Apo A-I), 29.003 |
GHD, GH-deficient; ISS, idiopathic short stature.
The most predictive peaks identified by regression analysis at start, after 1 year, and during the first year of GH treatment. For each model, the R2-value and cross-validated R2 are presented.